Summary
Boston Scientific Corporation (BSX) filed an 8-K report on October 19, 2004, to announce its financial results for the third quarter ended September 30, 2004. The primary purpose of this filing is to furnish a press release detailing these results, as this information is material to investors. Investors should refer to the press release, attached as Exhibit 99.1, for specific financial performance figures and commentary from the company. While the 8-K itself does not contain the detailed financial data, it officially signals the public release of this information. This includes key metrics such as revenue, net income, and earnings per share for the quarter, as well as any forward-looking statements or guidance the company provided. Investors are advised to review the press release to understand the company's performance in the third quarter of 2004 and its implications for future financial health and strategic direction.
Key Highlights
- 1Boston Scientific Corporation filed an 8-K on October 19, 2004, reporting its financial results for the third quarter ended September 30, 2004.
- 2The filing primarily serves to attach the company's official press release announcing these quarterly results (Exhibit 99.1).
- 3Investors need to consult the press release (Exhibit 99.1) for specific financial performance data, including revenue, earnings, and other key metrics.
- 4This report is considered an 'Item 2.02 Results of Operations and Financial Condition' filing.
- 5The information furnished in the 8-K and its exhibit is not considered 'filed' for Section 18 of the Exchange Act, meaning it does not carry the same legal liability as a formally filed statement.
- 6The filing also includes Item 9.01, which formally lists the financial statements and exhibits, specifically the press release.
- 7The report was signed by Lawrence J. Knopf, Vice President and Assistant General Counsel, indicating official company authorization.